Michigan late-stage biopharma, Sling Therapeutics, said a Phase IIb/III LIDS trial of its oral small molecule therapy designed to treat thyroid eye disease (TED) met its primary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback